Armin Ghobadi

2013–2025 年に発表

81
論文数
21,519
被引用数
42
h 指数
79
i10 指数

被引用数

Armin Ghobadi の年別被引用数1990 年: 被引用 1 件1992 年: 被引用 1 件2001 年: 被引用 3 件2005 年: 被引用 1 件2006 年: 被引用 2 件2013 年: 被引用 1 件2014 年: 被引用 2 件2015 年: 被引用 3 件2016 年: 被引用 4 件2017 年: 被引用 43 件2018 年: 被引用 150 件2019 年: 被引用 651 件2020 年: 被引用 1,179 件2021 年: 被引用 1,400 件2022 年: 被引用 1,475 件2023 年: 被引用 1,354 件2024 年: 被引用 2,149 件2025 年: 被引用 1,208 件2026 年: 被引用 28 件1991 年は被引用が無いため表示していません1993〜2000 年は被引用が無いため表示していません2002〜2004 年は被引用が無いため表示していません2007〜2012 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,076 件、この内訳の 31.8%中国: 引用元論文 1,054 件、この内訳の 10.9%ドイツ: 引用元論文 690 件、この内訳の 7.1%イギリス: 引用元論文 501 件、この内訳の 5.2%フランス: 引用元論文 454 件、この内訳の 4.7%イタリア: 引用元論文 450 件、この内訳の 4.7%スペイン: 引用元論文 385 件、この内訳の 4%カナダ: 引用元論文 284 件、この内訳の 2.9%オーストラリア: 引用元論文 238 件、この内訳の 2.5%スイス: 引用元論文 227 件、この内訳の 2.3%オランダ: 引用元論文 222 件、この内訳の 2.3%日本: 引用元論文 172 件、この内訳の 1.8%
0%31.8%その他 19.8%

分野

  • Medicine90.1%
  • Biochemistry, Genetics and Molecular Biology4.3%
  • Immunology and Microbiology4.2%
  • Engineering0.6%
  • Materials Science0.2%
  • Mathematics0.1%
  • その他0.5%

トピック

  • CAR-T cell therapy research27%
  • Virus-based gene therapy research6.6%
  • Lymphoma Diagnosis and Treatment5.5%
  • Immune Cell Function and Interaction5.2%
  • Nanowire Synthesis and Applications4.4%
  • Viral Infectious Diseases and Gene Expression in Insects3.9%
  • その他47.4%

共著者

全論文

検索で開く
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 被引用: 5,915

  2. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    著者: , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2018 被引用: 3,445

  3. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason R. Westin - New England Journal of Medicine 2021 被引用: 1,520

  4. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sattva S. Neelapu - The Lancet Oncology 2018 被引用: 2,251

  5. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roch Houot - The Lancet 2021 被引用: 769

  6. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 786

  7. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 410

  8. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , - Blood Advances 2020 被引用: 455

  9. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 228

  10. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dzmitry G. Batrakou, Erin Van Winkle, Erica Elefant, Armin Ghobadi, Amanda F. Cashen, Anne Grand’Maison, Philip L. McCarthy, Paula M. Fracasso, Elliot Norry, Dennis Williams, Mihaela Druta, David A. Liebner, Kunle Odunsi, Marcus O. Butler - Nature Medicine 2023 被引用: 194

  11. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

    著者: , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2022 被引用: 181

  12. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 198

  13. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 176

  14. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 200

  15. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

    著者: , , , , , , , , , , , , , , , , , , , , - Leukemia 2018 被引用: 394

  16. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    著者: , , , , , , , , , , , , , , , - Molecular Therapy 2017 被引用: 619

  17. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elias Jabbour - New England Journal of Medicine 2024 被引用: 196

  18. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Madina Sukhanova, Randall W. Knoebel, Wendy Stock, Timothy A. Graubert, Matthew J. Walter, Peter Westervelt, Daniel C. Link, John F. DiPersio, Timothy J. Ley - New England Journal of Medicine 2016 被引用: 784

  19. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

    著者: , , , , , , , , , , , , , , , , - The Lancet 2025 被引用: 113

  20. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Armin Ghobadi, Peter Westervelt, Keith Stockerl‐Goldstein, Mark A. Schroeder, Fei Wan, Wen‐Rong Lie, Patrick Soon‐Shiong, Allegra A. Petti, Amanda F. Cashen, Todd A. Fehniger - Science Translational Medicine 2022 被引用: 119

  21. Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , - Blood 2021 被引用: 82

  22. CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

    著者: , , , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 53

  23. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Hematology & Oncology 2022 被引用: 76

  24. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

    著者: , , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 88